Clinical Trial Update: Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. [EARLY_Phase 1]

View source ↗

Summary

An early-phase study is evaluating autologous CD84 CAR-T cell therapy for adults with relapsed or refractory acute myeloid leukemia; the trial status is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Autologous CD84 CAR-T cell therapy (CD84-targeted CAR-T cell therapy)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Relapsed/Refractory Acute Myeloid Leukemia(AML) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING